中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

扩大慢性乙型肝炎治疗

庄辉

引用本文:
Citation:

扩大慢性乙型肝炎治疗

DOI: 10.3969/j.issn.1001-5256.2023.01.001
利益冲突声明:作者声明不存在利益冲突。
详细信息
    通信作者:

    庄辉,zhuangbmu@126.com

Expanding the treatment of chronic hepatitis B

More Information
  • 摘要:

    全球符合治疗标准的慢性乙型肝炎患者中,仅5%接受抗病毒治疗。现行指南治疗标准过严是慢性乙型肝炎患者治疗率低的原因之一。扩大现行指南确定的慢性乙型肝炎治疗标准将减轻疾病负担。普遍乙型肝炎疫苗免疫、普遍筛查及对所有HBV DNA阳性者治疗,将有助于达到世界卫生组织提出的2030年消除乙型肝炎目标。

     

  • 图  1  全球HBV感染和疾病负担(引自参考文献[1])

    Figure  1.  Global HBV infection and disease burden (cited from reference[1])

    图  2  慢性HBV感染者治疗(引自参考文献[13])

    Figure  2.  Treatment of patients with chronic HBV infection (cited from reference[13])

    图  3  慢性HBV感染者4种治疗策略的治疗率(引自参考文献[14])

    Figure  3.  Treatment rate of four treatment strategies for patients with chronic HBV infection (cited in reference[14])

    图  4  3种简化治疗策略比较(引自参考文献[16])

    Figure  4.  Comparison of three simplified treatment strategies (cited from reference[16])

  • [1] SORIANO V, ALVAREZ C, EDAGWA B, et al. Ultra-long-acting (XLA) antivirals for chronic viral hepatitis[J]. Int J Infect Dis, 2022, 114: 45-50. DOI: 10.1016/j.ijid.2021.10.052.
    [2] World Health Organization. Global hepatitis report, 2017[R]. Geneva: World Health Organization, 2017.
    [3] World Health Organization. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030[R]. Geneva: World Health Organization, 2022.
    [4] Polaris Observatory HBV Collaborators[EB/OL]. [2022-11-10]. https://cdafound.org/dashboard/polaris/dashboard.html.
    [5] SINN DH, KIM SE, KIM BK, et al. The risk of hepatocellular carcinoma among chronic hepatitis B virus-infected patients outside current treatment criteria[J]. J Viral Hepat, 2019, 26(12): 1465-1472. DOI: 10.1111/jvh.13185.
    [6] SARIN SK, KUMAR M, LAU GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update[J]. Hepatol Int, 2016, 10(1): 1-98. DOI: 10.1007/s12072-015-9675-4.
    [7] TERRAULT NA, LOK A, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800.
    [8] European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398. DOI: 10.1016/j.jhep.2017.03.021.
    [9] PAPATHEODORIDIS GV, LAMPERTICO P, MANOLAKOPOULOS S, et al. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review[J]. J Hepatol, 2010, 53(2): 348-356. DOI: 10.1016/j.jhep.2010.02.035.
    [10] PAPATHEODORIDIS GV, IDILMAN R, DALEKOS GN, et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B[J]. Hepatology, 2017, 66(5): 1444-1453. DOI: 10.1002/hep.29320.
    [11] CHEN YC, CHU CM, LIAW YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B[J]. Hepatology, 2010, 51(2): 435-444. DOI: 10.1002/hep.23348.
    [12] YUEN MF, WONG DK, FUNG J, et al. HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma[J]. Gastroenterology, 2008, 135(4): 1192-1199. DOI: 10.1053/j.gastro.2008.07.008.
    [13] CHOI H, TONTHAT A, JANSSEN H, et al. Aiming for functional cure with established and novel therapies for chronic hepatitis B[J]. Hepatol Commun, 2022, 6(5): 935-949. DOI: 10.1002/hep4.1875.
    [14] WONG RJ, KAUFMAN HW, NILES JK, et al. Simplifying treatment criteria in chronic hepatitis B: Reducing barriers to elimination[J]. Clin Infect Dis, 2022. DOI: 10.1093/cid/ciac385.[Onlineaheadofprint]
    [15] TONG MJ, PAN CQ, HAN SB, et al. An expert consensus for the management of chronic hepatitis B in Asian Americans[J]. Aliment Pharmacol Ther, 2018, 47(8): 1181-1200. DOI: 10.1111/apt.14577.
    [16] RAZAVI-SHEARER D, ESTES C, GAMKRELIDZE I, et al. Cost-effectiveness analysis of treating all HBsAg+ individuals in the United States[J]. Hepatology, 2021, 74(Suppl 1): 22A.
    [17] LIM YS, AHN SH, SHIM JJ, et al. Impact of expanding hepatitis B treatment guidelines: A modelling and economic impact analysis[J]. Aliment Pharmacol Ther, 2022, 56(3): 519-528. DOI: 10.1111/apt.17052.
    [18] Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study[J]. Lancet Gastroenterol Hepatol, 2018, 3(6): 383-403. DOI: 10.1016/S2468-1253(18)30056-6.
    [19] TOY M, HUTTON D, HARRIS AM, et al. Cost-effectiveness of 1-time universal screening for chronic hepatitis B infection in adults in the United States[J]. Clin Infect Dis, 2022, 74(2): 210-217. DOI: 10.1093/cid/ciab405.
    [20] RAMRAKHIANI NS, CHEN VL, LE M, et al. Optimizing hepatitis B virus screening in the United States using a simple demographics-based model[J]. Hepatology, 2022, 75(2): 430-437. DOI: 10.1002/hep.32142.
    [21] SU S, WONG WC, ZOU Z, et al. Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation[J]. Lancet Glob Health, 2022, 10(2): e278-e287. DOI: 10.1016/S2214-109X(21)00517-9.
    [22] WENG MK, DOSHANI M, KHAN MA, et al. Universal hepatitis B vaccination in adults aged 19-59 years: Updated recommendations of the advisory committee on immunization practices-United States, 2022[J]. MMWR Morb Mortal Wkly Rep, 2022, 71(13): 477-483. DOI: 10.15585/mmwr.mm7113a1.
  • 加载中
图(4)
计量
  • 文章访问数:  2536
  • HTML全文浏览量:  1488
  • PDF下载量:  426
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-11-18
  • 出版日期:  2023-01-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回